Share Price and Basic Stock Data
Last Updated: February 9, 2026, 9:30 pm
| PEG Ratio | -4.38 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Cohance Lifesciences Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹14,182 Cr. The company reported a price of ₹371 per share, reflecting a P/E ratio of 41.3, indicating a premium valuation compared to typical industry standards. Revenues have shown a fluctuating trend, with sales recorded at ₹1,340 Cr for the fiscal year ending March 2023, followed by a decline to ₹1,051 Cr in March 2024, and a recovery projected to ₹1,198 Cr in March 2025. The trailing twelve months (TTM) revenue stood at ₹2,252 Cr, indicating a potential rebound in operational performance. Notably, sales in the latest quarter ended September 2023 fell to ₹231 Cr, raising concerns over short-term demand. Over the last few quarters, the company’s quarterly sales peaked at ₹604 Cr in September 2024, showcasing its ability to generate significant revenue during certain periods. The volatility in quarterly figures suggests a need for strategic adjustments to stabilize revenue growth.
Profitability and Efficiency Metrics
Cohance Lifesciences reported a net profit of ₹313 Cr, translating to a net profit margin of 22.10% for the fiscal year ending March 2025. This figure indicates solid profitability, although it has been on a downward trend from 30.68% in March 2023 and 31.25% in March 2022. The operating profit margin (OPM) for March 2025 stood at 31%, a significant decline from 43% in March 2023, reflecting increased operational costs or pricing pressures. The company’s efficiency metrics show a cash conversion cycle (CCC) of 190 days, which is relatively high compared to industry norms, indicating potential liquidity challenges. Return on equity (ROE) was reported at 12.7%, and return on capital employed (ROCE) at 14.9%, both of which are reasonable but suggest that the company could enhance capital utilization. Overall, while profitability metrics remain respectable, the declining margins warrant attention to operational efficiency.
Balance Sheet Strength and Financial Ratios
Cohance Lifesciences has a balanced financial structure, with total assets reported at ₹5,568 Cr and total borrowings at ₹451 Cr, resulting in a low debt-to-equity ratio of 0.04. This indicates a conservative approach to leveraging, positioning the company favorably in terms of financial health. Reserves have increased to ₹3,749 Cr, providing a solid foundation for future investments or cushioning against downturns. The interest coverage ratio (ICR) is particularly strong at 35.12x, illustrating the company’s ability to comfortably meet interest obligations. However, the price-to-book value (P/BV) stands at 17.40x, which is high and may indicate overvaluation relative to its book value. The company’s liquidity ratios are robust, with a current ratio of 2.43 and a quick ratio of 1.98, suggesting a strong ability to cover short-term liabilities. While the balance sheet appears healthy, the high P/BV ratio may deter some value-focused investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Cohance Lifesciences reveals a significant level of promoter ownership at 57.49%, which reflects strong management commitment to the company. Foreign institutional investors (FIIs) hold 6.51%, while domestic institutional investors (DIIs) have a more substantial stake at 20.81%, indicating confidence in the company’s long-term prospects. The public holds 15.16%, with a total of 75,284 shareholders, suggesting a broad base of retail interest. However, the promoter shareholding has seen fluctuations, declining from 60% in early 2023, which could raise concerns regarding management stability. The decrease in FII holdings from a peak of 11.05% in March 2025 to the current level may signal caution among foreign investors, potentially due to the company’s recent performance fluctuations. Overall, while the shareholding structure reflects a stable core, the shifts in institutional ownership may influence market sentiment.
Outlook, Risks, and Final Insight
Cohance Lifesciences faces several opportunities and challenges as it navigates its operational landscape. The company has demonstrated resilience in revenue generation, particularly with a TTM revenue of ₹2,252 Cr, but the recent quarterly decline raises concerns about demand sustainability. Key risks include the declining profit margins and high cash conversion cycle, which could hinder liquidity and operational flexibility. Moreover, the high P/BV ratio suggests potential overvaluation, which may deter new investments. On the upside, the strong balance sheet provides a buffer for strategic initiatives, and the robust interest coverage ratio ensures financial stability. If the company can stabilize its revenue and enhance operational efficiency, it may present an attractive investment. Conversely, failure to address the underlying issues affecting profitability could lead to further declines in market confidence. The strategic focus on improving margins and managing operational costs will be critical for future success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 185/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,651 Cr. | 336 | 479/192 | 76.4 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.4 Cr. | 42.4 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.1 Cr. | 54.0 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,103.62 Cr | 1,117.07 | 54.60 | 201.93 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 278 | 354 | 369 | 348 | 231 | 220 | 253 | 488 | 604 | 307 | 840 | 549 | 556 |
| Expenses | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 398 | 189 | 611 | 437 | 435 |
| Operating Profit | 100 | 147 | 172 | 167 | 98 | 66 | 73 | 125 | 205 | 118 | 229 | 112 | 121 |
| OPM % | 36% | 41% | 47% | 48% | 42% | 30% | 29% | 26% | 34% | 38% | 27% | 20% | 22% |
| Other Income | 11 | 13 | 11 | 11 | 20 | 14 | 17 | 19 | 16 | 16 | -4 | 6 | 16 |
| Interest | 0 | 1 | 5 | 1 | 0 | 2 | 2 | 10 | 10 | 3 | 10 | 10 | 9 |
| Depreciation | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 38 | 20 | 54 | 45 | 44 |
| Profit before tax | 98 | 146 | 166 | 164 | 105 | 65 | 71 | 103 | 174 | 110 | 161 | 63 | 84 |
| Tax % | 27% | 26% | 25% | 26% | 25% | 29% | 25% | 27% | 21% | 24% | 27% | 26% | 21% |
| Net Profit | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 138 | 83 | 117 | 46 | 66 |
| EPS in Rs | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 5.44 | 3.26 | 4.73 | 1.28 | 1.94 |
Last Updated: December 28, 2025, 11:04 pm
Below is a detailed analysis of the quarterly data for Cohance Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 556.00 Cr.. The value appears strong and on an upward trend. It has increased from 549.00 Cr. (Jun 2025) to 556.00 Cr., marking an increase of 7.00 Cr..
- For Expenses, as of Sep 2025, the value is 435.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 437.00 Cr. (Jun 2025) to 435.00 Cr., marking a decrease of 2.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 112.00 Cr. (Jun 2025) to 121.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 20.00% (Jun 2025) to 22.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Jun 2025) to 16.00 Cr., marking an increase of 10.00 Cr..
- For Interest, as of Sep 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Jun 2025) to 9.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 44.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 45.00 Cr. (Jun 2025) to 44.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 63.00 Cr. (Jun 2025) to 84.00 Cr., marking an increase of 21.00 Cr..
- For Tax %, as of Sep 2025, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 21.00%, marking a decrease of 5.00%.
- For Net Profit, as of Sep 2025, the value is 66.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Jun 2025) to 66.00 Cr., marking an increase of 20.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.94. The value appears strong and on an upward trend. It has increased from 1.28 (Jun 2025) to 1.94, marking an increase of 0.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:33 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 1,198 | 2,252 |
| Expenses | 206 | 449 | 567 | 738 | 766 | 645 | 822 | 1,673 |
| Operating Profit | 172 | 385 | 443 | 582 | 574 | 406 | 375 | 580 |
| OPM % | 45% | 46% | 44% | 44% | 43% | 39% | 31% | 26% |
| Other Income | 1 | 66 | 68 | 133 | 46 | 62 | 58 | 34 |
| Interest | 3 | 23 | 12 | 9 | 13 | 7 | 12 | 33 |
| Depreciation | 12 | 24 | 32 | 39 | 48 | 55 | 77 | 164 |
| Profit before tax | 158 | 405 | 468 | 668 | 560 | 406 | 344 | 417 |
| Tax % | 31% | 22% | 23% | 32% | 27% | 26% | 23% | |
| Net Profit | 109 | 317 | 362 | 454 | 411 | 300 | 265 | 313 |
| EPS in Rs | 12.45 | 14.23 | 17.83 | 16.16 | 11.80 | 10.52 | 11.21 | |
| Dividend Payout % | 0% | 20% | 14% | 28% | 37% | 0% | 0% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 190.83% | 14.20% | 25.41% | -9.47% | -27.01% | -11.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -176.63% | 11.22% | -34.89% | -17.54% | 15.34% |
Cohance Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | -3% |
| TTM: | 64% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -16% |
| TTM: | 38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 23% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 17% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: February 1, 2026, 2:00 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.00 | 13 | 25 | 25 | 25 | 25 | 25 | 38 |
| Reserves | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 | 3,749 |
| Borrowings | 83 | 186 | 143 | 97 | 70 | 65 | 279 | 451 |
| Other Liabilities | 123 | 142 | 151 | 205 | 160 | 138 | 1,056 | 1,330 |
| Total Liabilities | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,568 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 | 3,116 |
| CWIP | 111 | 102 | 96 | 30 | 165 | 179 | 256 | 357 |
| Investments | 7 | 338 | 542 | 598 | 536 | 904 | 337 | 454 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 725 | 1,641 |
| Total Assets | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,568 |
Below is a detailed analysis of the balance sheet data for Cohance Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 38.00 Cr., marking an increase of 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,749.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,671.00 Cr. (Mar 2025) to 3,749.00 Cr., marking an increase of 2,078.00 Cr..
- For Borrowings, as of Sep 2025, the value is 451.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 279.00 Cr. (Mar 2025) to 451.00 Cr., marking an increase of 172.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,330.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,056.00 Cr. (Mar 2025) to 1,330.00 Cr., marking an increase of 274.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,568.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,031.00 Cr. (Mar 2025) to 5,568.00 Cr., marking an increase of 2,537.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,116.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,713.00 Cr. (Mar 2025) to 3,116.00 Cr., marking an increase of 1,403.00 Cr..
- For CWIP, as of Sep 2025, the value is 357.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 101.00 Cr..
- For Investments, as of Sep 2025, the value is 454.00 Cr.. The value appears strong and on an upward trend. It has increased from 337.00 Cr. (Mar 2025) to 454.00 Cr., marking an increase of 117.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,641.00 Cr.. The value appears strong and on an upward trend. It has increased from 725.00 Cr. (Mar 2025) to 1,641.00 Cr., marking an increase of 916.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,568.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,031.00 Cr. (Mar 2025) to 5,568.00 Cr., marking an increase of 2,537.00 Cr..
Notably, the Reserves (3,749.00 Cr.) exceed the Borrowings (451.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 89.00 | 199.00 | 300.00 | 485.00 | 504.00 | 341.00 | 96.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 142 | 51 | 37 | 65 | 30 | 46 | 87 |
| Inventory Days | 556 | 278 | 243 | 259 | 279 | 268 | 199 |
| Days Payable | 190 | 113 | 100 | 97 | 63 | 49 | 96 |
| Cash Conversion Cycle | 509 | 217 | 180 | 228 | 247 | 265 | 190 |
| Working Capital Days | 205 | 64 | 56 | 108 | 99 | 108 | 74 |
| ROCE % | 50% | 40% | 41% | 32% | 19% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Balanced Advantage Fund | 4,143,548 | 0.2 | 219.03 | 3,353,052 | 2026-01-26 01:55:12 | 23.58% |
| HDFC Flexi Cap Fund | 4,000,000 | 0.22 | 211.44 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 3,672,095 | 3.01 | 194.11 | 3,068,016 | 2026-01-26 01:55:12 | 19.69% |
| Invesco India Contra Fund | 3,598,511 | 0.92 | 190.22 | 3,323,946 | 2025-12-15 01:49:31 | 8.26% |
| DSP ELSS Tax Saver Fund | 3,285,254 | 0.99 | 173.66 | 1,910,066 | 2025-12-07 02:39:30 | 72% |
| DSP Healthcare Fund | 2,967,600 | 5.04 | 156.87 | 2,489,539 | 2025-12-07 02:39:30 | 19.2% |
| DSP Large & Mid Cap Fund | 2,762,648 | 0.83 | 146.03 | N/A | N/A | N/A |
| Axis Small Cap Fund | 2,540,619 | 0.51 | 134.3 | 2,026,449 | 2025-12-07 02:39:30 | 25.37% |
| DSP Flexi Cap Fund | 2,453,891 | 1.05 | 129.71 | 1,830,535 | 2025-12-07 02:39:30 | 34.05% |
| Canara Robeco Small Cap Fund | 2,261,293 | 0.91 | 119.53 | 1,574,180 | 2025-12-07 02:39:30 | 43.65% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 10.52 | 11.80 | 16.16 | 17.83 | 14.23 |
| Diluted EPS (Rs.) | 10.45 | 11.80 | 16.16 | 17.83 | 14.23 |
| Cash EPS (Rs.) | 13.44 | 13.94 | 18.03 | 17.75 | 13.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 66.64 | 80.56 | 68.16 | 59.99 | 46.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 66.64 | 80.56 | 68.16 | 59.99 | 46.39 |
| Revenue From Operations / Share (Rs.) | 47.04 | 41.30 | 52.65 | 51.86 | 39.66 |
| PBDIT / Share (Rs.) | 17.04 | 18.37 | 24.08 | 26.39 | 17.86 |
| PBIT / Share (Rs.) | 13.99 | 16.23 | 22.20 | 24.85 | 16.62 |
| PBT / Share (Rs.) | 13.51 | 15.94 | 21.99 | 24.61 | 16.26 |
| Net Profit / Share (Rs.) | 10.40 | 11.80 | 16.16 | 16.21 | 12.12 |
| NP After MI And SOA / Share (Rs.) | 10.52 | 11.80 | 16.16 | 17.83 | 14.23 |
| PBDIT Margin (%) | 36.21 | 44.48 | 45.72 | 50.88 | 45.03 |
| PBIT Margin (%) | 29.74 | 39.29 | 42.16 | 47.92 | 41.90 |
| PBT Margin (%) | 28.71 | 38.58 | 41.76 | 47.45 | 40.99 |
| Net Profit Margin (%) | 22.10 | 28.56 | 30.68 | 31.25 | 30.56 |
| NP After MI And SOA Margin (%) | 22.36 | 28.56 | 30.68 | 34.37 | 35.88 |
| Return on Networth / Equity (%) | 15.78 | 14.64 | 23.70 | 29.71 | 30.68 |
| Return on Capital Employeed (%) | 13.36 | 19.24 | 31.27 | 39.07 | 33.71 |
| Return On Assets (%) | 8.83 | 13.32 | 20.92 | 24.80 | 24.57 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| Total Debt / Equity (X) | 0.04 | 0.01 | 0.04 | 0.06 | 0.11 |
| Asset Turnover Ratio (%) | 0.45 | 0.49 | 0.70 | 0.80 | 0.79 |
| Current Ratio (X) | 2.43 | 11.82 | 6.37 | 5.36 | 2.57 |
| Quick Ratio (X) | 1.98 | 9.65 | 4.40 | 4.02 | 1.66 |
| Inventory Turnover Ratio (X) | 6.02 | 3.87 | 1.44 | 1.90 | 1.65 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 49.51 | 22.43 | 7.02 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 44.36 | 20.65 | 6.46 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 50.49 | 77.57 | 92.98 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 55.64 | 79.35 | 93.54 |
| Interest Coverage Ratio (X) | 35.12 | 62.77 | 112.74 | 107.82 | 49.73 |
| Interest Coverage Ratio (Post Tax) (X) | 22.44 | 41.30 | 76.66 | 67.23 | 34.75 |
| Enterprise Value (Cr.) | 29662.03 | 17211.94 | 12039.36 | 15779.11 | 12742.73 |
| EV / Net Operating Revenue (X) | 24.77 | 16.37 | 8.98 | 11.95 | 12.62 |
| EV / EBITDA (X) | 68.38 | 36.80 | 19.64 | 23.49 | 28.02 |
| MarketCap / Net Operating Revenue (X) | 24.66 | 16.38 | 8.98 | 11.92 | 12.49 |
| Retention Ratios (%) | 0.00 | 0.00 | 50.48 | 77.56 | 92.97 |
| Price / BV (X) | 17.40 | 8.40 | 6.93 | 10.30 | 10.68 |
| Price / Net Operating Revenue (X) | 24.66 | 16.38 | 8.98 | 11.92 | 12.49 |
| EarningsYield | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 |
After reviewing the key financial ratios for Cohance Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.52, marking a decrease of 1.28.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.45. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.45, marking a decrease of 1.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 13.44. This value is within the healthy range. It has decreased from 13.94 (Mar 24) to 13.44, marking a decrease of 0.50.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.64. It has decreased from 80.56 (Mar 24) to 66.64, marking a decrease of 13.92.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.64. It has decreased from 80.56 (Mar 24) to 66.64, marking a decrease of 13.92.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 47.04. It has increased from 41.30 (Mar 24) to 47.04, marking an increase of 5.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 17.04. This value is within the healthy range. It has decreased from 18.37 (Mar 24) to 17.04, marking a decrease of 1.33.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.99. This value is within the healthy range. It has decreased from 16.23 (Mar 24) to 13.99, marking a decrease of 2.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.51. This value is within the healthy range. It has decreased from 15.94 (Mar 24) to 13.51, marking a decrease of 2.43.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.40. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.40, marking a decrease of 1.40.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.52, marking a decrease of 1.28.
- For PBDIT Margin (%), as of Mar 25, the value is 36.21. This value is within the healthy range. It has decreased from 44.48 (Mar 24) to 36.21, marking a decrease of 8.27.
- For PBIT Margin (%), as of Mar 25, the value is 29.74. This value exceeds the healthy maximum of 20. It has decreased from 39.29 (Mar 24) to 29.74, marking a decrease of 9.55.
- For PBT Margin (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has decreased from 38.58 (Mar 24) to 28.71, marking a decrease of 9.87.
- For Net Profit Margin (%), as of Mar 25, the value is 22.10. This value exceeds the healthy maximum of 10. It has decreased from 28.56 (Mar 24) to 22.10, marking a decrease of 6.46.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 22.36. This value exceeds the healthy maximum of 20. It has decreased from 28.56 (Mar 24) to 22.36, marking a decrease of 6.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.78. This value is within the healthy range. It has increased from 14.64 (Mar 24) to 15.78, marking an increase of 1.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.36. This value is within the healthy range. It has decreased from 19.24 (Mar 24) to 13.36, marking a decrease of 5.88.
- For Return On Assets (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has decreased from 13.32 (Mar 24) to 8.83, marking a decrease of 4.49.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.04, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.45. It has decreased from 0.49 (Mar 24) to 0.45, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.43. This value is within the healthy range. It has decreased from 11.82 (Mar 24) to 2.43, marking a decrease of 9.39.
- For Quick Ratio (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 9.65 (Mar 24) to 1.98, marking a decrease of 7.67.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.02. This value is within the healthy range. It has increased from 3.87 (Mar 24) to 6.02, marking an increase of 2.15.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.12. This value is within the healthy range. It has decreased from 62.77 (Mar 24) to 35.12, marking a decrease of 27.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 22.44. This value is within the healthy range. It has decreased from 41.30 (Mar 24) to 22.44, marking a decrease of 18.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 29,662.03. It has increased from 17,211.94 (Mar 24) to 29,662.03, marking an increase of 12,450.09.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 24.77. This value exceeds the healthy maximum of 3. It has increased from 16.37 (Mar 24) to 24.77, marking an increase of 8.40.
- For EV / EBITDA (X), as of Mar 25, the value is 68.38. This value exceeds the healthy maximum of 15. It has increased from 36.80 (Mar 24) to 68.38, marking an increase of 31.58.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 24.66. This value exceeds the healthy maximum of 3. It has increased from 16.38 (Mar 24) to 24.66, marking an increase of 8.28.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 17.40. This value exceeds the healthy maximum of 3. It has increased from 8.40 (Mar 24) to 17.40, marking an increase of 9.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 24.66. This value exceeds the healthy maximum of 3. It has increased from 16.38 (Mar 24) to 24.66, marking an increase of 8.28.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cohance Lifesciences Ltd:
- Net Profit Margin: 22.1%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.36% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.78% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 22.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.98
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.8 (Industry average Stock P/E: 54.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 22.1%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vivek Sharma | Executive Chairman |
| Dr. V Prasada Raju | Managing Director |
| Mr. Pankaj Patwari | Non Executive Director |
| Ms. Shweta Jalan | Non Executive Director |
| Mr. Vinod Padikkal | Non Executive Director |
| Mr. Vinod Rao | Independent Director |
| Mr. K G Ananthakrishnan | Independent Director |
| Mr. U B Pravin Rao | Independent Director |
| Ms. Matangi Gowrishankar | Independent Director |
| Mr. Jai Shankar Krishnan | Independent Director |
FAQ
What is the intrinsic value of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd's intrinsic value (as of 09 February 2026) is ₹362.79 which is 3.95% higher the current market price of ₹349.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹13,346 Cr. market cap, FY2025-2026 high/low of ₹1,328/334, reserves of ₹3,749 Cr, and liabilities of ₹5,568 Cr.
What is the Market Cap of Cohance Lifesciences Ltd?
The Market Cap of Cohance Lifesciences Ltd is 13,346 Cr..
What is the current Stock Price of Cohance Lifesciences Ltd as on 09 February 2026?
The current stock price of Cohance Lifesciences Ltd as on 09 February 2026 is ₹349.
What is the High / Low of Cohance Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Cohance Lifesciences Ltd stocks is ₹1,328/334.
What is the Stock P/E of Cohance Lifesciences Ltd?
The Stock P/E of Cohance Lifesciences Ltd is 38.8.
What is the Book Value of Cohance Lifesciences Ltd?
The Book Value of Cohance Lifesciences Ltd is 99.0.
What is the Dividend Yield of Cohance Lifesciences Ltd?
The Dividend Yield of Cohance Lifesciences Ltd is 0.00 %.
What is the ROCE of Cohance Lifesciences Ltd?
The ROCE of Cohance Lifesciences Ltd is 14.9 %.
What is the ROE of Cohance Lifesciences Ltd?
The ROE of Cohance Lifesciences Ltd is 12.7 %.
What is the Face Value of Cohance Lifesciences Ltd?
The Face Value of Cohance Lifesciences Ltd is 1.00.